Abstract: The present invention provides a combination comprising (a) a radiolabeled complex comprising a radionuclide and a targeting molecule linked to a chelating agent, and (b) para-aminohippuric acid (PAH) or a salt or derivate thereof for the treatment of cancer. Moreover, a pharmaceutical composition comprising (a) a radiolabeled complex comprising a radionuclide and a targeting molecule linked to a chelating agent, and (b) para-aminohippuric acid (PAH) or a salt or derivate thereof is provided for the treatment of cancer. The radiolabeled complex and PAH may be used in a combination therapy for the treatment of cancer.

Abstract: The present application discloses para-aminohippuric acid (PAhI) or a pharmaceutically acceptable salt or carboxylic acid derivate thereof for use in a method for the reduction of nephrotoxic side effects of radiolabeled and non-radiolabeled therapeutic and diagnostic compounds in a subject. Also disclosed are pharmaceutical compositions comprising a radiolabeled and/or non-radiolabeled pharmaceutical compound and para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivate thereof, and a pharmaceutically acceptable excipient, diluent, carrier or a combination thereof.

Abstract: A 68Ge/68Ga generator for a continuous production of a 68Ga daughter nuclide, wherein the 68Ge parent nuclide thereof is specifically adsorbed to an inorganic support material and wherein said 68Ge parent nuclide continuously decays to 68Ga by electron capture at a half-life of 270.82 d, wherein the inorganic support material is at least one oxide of a metal being selected from the group consisting of: Vanadium, Niobium and Tantalum. The use of at least one oxide of a metal being selected from the group consisting of: Vanadium, Niobium and Tantalum as an inorganic support material for the manufacture of a 68Ge/68Ga generator for pharmaceutical purposes. With the inorganic support material of the present invention, it is possible to load 68Ge/68Ga generators with up to 8000 MBq of 68Ge (corresponding to 80 ?g Germanium).

Abstract: The invention relates to a compound V for complexing metallic isotopes, comprising a chelator X and one or more targeting vectors conjugated with the chelator X, said targeting vectors having the structure -L1-R1-L2-R2-L3-R3, wherein R3 contains a bisphosphonate. A pharmaceutical consists of the compound V and a metallic isotope which is complexed with compound V.

Abstract: A 68Ge/68Ga generator for a continuous production of a 68Ga daughter nuclide, wherein the 68Ge parent nuclide thereof is specifically adsorbed to an inorganic support material and wherein said 68Ge parent nuclide continuously decays to 68Ga by electron capture at a half-life of 270.82 d, wherein the inorganic support material is at least one oxide of a metal being selected from the group consisting of: Vanadium, Niobium and Tantalum. The use of at least one oxide of a metal being selected from the group consisting of: Vanadium, Niobium and Tantalum as an inorganic support material for the manufacture of a 68Ge/68Ga generator for pharmaceutical purposes. With the inorganic support material of the present invention, it is possible to load 68Ge/68Ga generators with up to 8000 MBq of 68Ge (corresponding to 80 ?g Germanium).

Abstract: The invention relates to a compound V for complexing metallic isotopes, comprising a chelator X and one or more targeting vectors conjugated with the chelator X, said targeting vectors having the structure -L1-R1-L2-R2-L3-R3, wherein R3 contains a bisphosphonate. A pharmaceutical consists of the compound V and a metallic isotope which is complexed with compound V.